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Purpose: Second malignancies (SMs) after radiation therapy are rare but serious sequelae of
treatment. This study investigates whether radiation therapy use is associated with changes in
baseline SM risk.
Methods and Materials: We extracted all patients with cancer, with or without SM, in the
Surveillance, Epidemiology, and End Results database from 1973 to 2014. Cumulative inci-
dence of SM for patients stratified by radiation therapy status was calculated using a competing
risk model, both for the entire cohort and for subgroups based on the primary tumor’s anatomic
location.
Results: We identified 2,872,063 patients with cancer, including 761,289 patients who received
radiation therapy and 2,110,774 who did not. The SM rate at 20 years for patients receiving
radiation therapy versus no radiation therapy was 21.4% versus 18.8%. The relative risk for SM
associated with radiation therapy for the overall group was 1.138 at 20 years. The relative risks for
SM associated with radiation therapy to malignancies arising from central nervous system and
orbits, head and neck, thorax, abdomen, and pelvis at 20 years were 0.704, 1.011, 0.559, 0.646, and
1.106 for men and 0.792, 1.298, 1.265, 0.780, and 0.988 for women, respectively.
Conclusions: The association between SM and radiation therapy varies with both sex and disease
anatomic location, with the largest increase in SM seen in females irradiated to the head and neckSources of support: This work had no specific funding.
Disclosures: none.
* Corresponding author. Department of Radiation Oncology, Suite B265, 200 Medical Plaza, Los Angeles, CA 90095.
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with differences in various clinical contexts.
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Radiation exposure is a known precipitant of malig-
nancy, as determined by data from the Japanese atomic
bomb survivors1 and from individuals with occupational
radiation exposure.2 Similarly, previous studies of long-
term cancer survivors have also determined that radia-
tion therapy (RT) is associated with increased risk of
second malignancy (SM).3 Increased incidence or risk for
SM has been reported in pediatric,4 gynecologic,5e8
breast,9e13 prostate,14e16 and hematologic17e20 malig-
nancies treated with RT. Despite the strong evidence for
radiation-induced malignancy, existing literature has not
been able to accurately quantify the SM risk associated
with RT, which is presumed to be low and with an
indolent time course. Throughout the past decade, cancer
survival has significantly improved, attributed to both
early diagnosis and more effective treatment regimens,
exemplified by aggressive utilization of definitive thera-
pies including RT. Prolonged cancer survival also in-
creases the awareness of SMs, which are among the most
devastating late sequelae of RT and can take many years
to develop after treatment.
In this study, we attempted to estimate the relative risk
of SM for patients who received RT compared with those
who did not, using the entire Surveillance, Epidemiology,
and End Results (SEER) database, which provides a large
cohort size with decades-long follow-up. Our SM analysis
used a competing risk model, accounting for all-cause
mortality (ACM) as a competing risk event for SM. Given
the inherent variation in individual anatomy and dose
distribution, we combined all subsequent malignancies
after the first malignancy diagnosis as SMs to provide a
more accurate reference for the overall risk of SM after
RT. Finally, we grouped the primary disease sites using
an anatomically meaningful schema consisting of central
nervous system (CNS) and orbits, head and neck, thorax,
and abdomen and pelvis.Methods and Materials
Patient population
This study was reviewed and approved by the insti-
tutional review board at our institution. For this study, the
entire SEER database was used, which included patients
with malignancies diagnosed between January 1, 1973and December 31, 2014. Patients were excluded if they
(1) were not in active follow-up, (2) had unknown RT
status, or (3) received chemotherapy. Although this study
intends to restrict the study population to patients who
received no chemotherapy and to stratify the analysis
according to RT status, it is possible that some patients
who were recorded as having received no chemotherapy
or no RT may have received either treatment owing to an
inherent underascertainment issue associated with the
SEER database.
Previous studies have concluded that hematopoietic
SMs develop with a latency period of 2 years after radi-
ation exposure21 and solid SM are presumed to take
longer to present, which compelled several previous
studies to use a threshold of 5 years.14,22e27 For this
study, we excluded all cases with consecutive malig-
nancies that occurred within 2 years of each other because
the design of this study is to be inclusive of all possible
SM, including both hematopoietic and solid malignancies.
Extracted variables include age at diagnosis, sex, year of
diagnosis, race, and RT status.
Statistical methodology and analysis
To account for ACM as a competing risk for SM,
cumulative incidences of SM and ACM were computed via
a competing risk model. This was done for the entire SEER
database and subsequently repeated for subgroups based on
sex, age, and anatomic primary disease sites, defined as
CNS and orbits, head and neck, thorax, abdomen, and
pelvis. The distributions of the cumulative incidence of
SMs for cohorts stratified based on RT status were
evaluated via a k-sample test described by Gray et al,28
which compared the weighted average of the hazards of
the subdistribution for SM. Patients who were alive at last
follow-up were censored. All statistical analyses were
carried out using R version 3.3.2 (R Foundation for
Statistical Computing, Vienna, Austria) with 2-sided
testing and a statistical significance threshold of .05.
Results
Patient characteristics for the SEER cohort
The patient characteristics stratified by anatomic dis-
ease sites are shown in Table 1. A total of 2,872,063
patients from the SEER database who matched the
Table 1 Patient characteristics
Abdomen CNS and
orbit
Head and
neck
Pelvis Thorax P value
n 416,452 35,907 184,632 1,420,338 814,734
Age (y, median [IQR]) 67.00
[57.00, 76.00]
40.00
[21.00, 57.00]
56.00
[45.00, 67.00]
66.00
[57.00, 73.00]
63.00
[53.00, 73.00]
<.001
Sex, male/female (%) 218,642/197,810
(52.5/47.5)
19,542/16,365
(54.4/45.6)
94,399/90,233
(51.1/48.9)
1,071,149/349,189
(75.4/24.6)
73,665/741,069
(9.0/91.0)
<.001
Race (%) <.001
White 338,143 (81.2) 31,148 (86.7) 155,123 (84.0) 1,171,227 (82.5) 686,258 (84.2)
Black 42,974 (10.3) 2388 (6.7) 14,122 (7.6) 149,007 (10.5) 67,596 (8.3)
Asian/Pacific Islander 2530 (0.6) 237 (0.7) 883 (0.5) 5433 (0.4) 3169 (0.4)
Other unspecified 30,022 (7.2) 1675 (4.7) 12,444 (6.7) 69,899 (4.9) 53,190 (6.5)
Unknown 2783 (0.7) 459 (1.3) 2060 (1.1) 24,772 (1.7) 4521 (0.6)
Radiation, no/yes (%) 410,452/6000
(98.6/1.4)
22,436/13,471
(62.5/37.5)
122,430/62,202
(66.3/33.7)
1,035,560/384,778
(72.9/27.1)
519,896/294,838
(63.8/36.2)
<.001
SEER Registry (%) <.001
San Francisco-Oakland 34,856 (8.4) 3023 (8.4) 16,893 (9.1) 118,818 (8.4) 74,781 (9.2)
Connecticut 41,121 (9.9) 3037 (8.5) 17,417 (9.4) 115,635 (8.1) 79,305 (9.7)
Metropolitan Detroit 39,474 (9.5) 2888 (8.0) 17,569 (9.5) 137,425 (9.7) 79,713 (9.8)
Hawaii 11,872 (2.9) 761 (2.1) 5016 (2.7) 30,480 (2.1) 20,552 (2.5)
Iowa 32,778 (7.9) 2821 (7.9) 14,307 (7.7) 97,991 (6.9) 56,147 (6.9)
New Mexico 12,388 (3.0) 1261 (3.5) 6990 (3.8) 45,244 (3.2) 23,169 (2.8)
Seattle (Puget Sound) 29,592 (7.1) 3267 (9.1) 14,330 (7.8) 118,370 (8.3) 65,971 (8.1)
Utah 11,327 (2.7) 1929 (5.4) 7320 (4.0) 51,227 (3.6) 22,811 (2.8)
Metropolitan Atlanta 16,201 (3.9) 1735 (4.8) 8139 (4.4) 59,552 (4.2) 37,079 (4.6)
Alaska 618 (0.1) 37 (0.1) 155 (0.1) 742 (0.1) 763 (0.1)
San Jose-Monterey 9446 (2.3) 934 (2.6) 3805 (2.1) 37,160 (2.6) 20,755 (2.5)
Los Angeles 39,799 (9.6) 3258 (9.1) 15,782 (8.5) 140,366 (9.9) 75,582 (9.3)
Rural Georgia 654 (0.2) 44 (0.1) 293 (0.2) 2373 (0.2) 1247 (0.2)
Greater California 52,401 (12.6) 4575 (12.7) 21,255 (11.5) 187,209 (13.2) 107,961 (13.3)
Kentucky 16,559 (4.0) 1321 (3.7) 6727 (3.6) 48,541 (3.4) 27,907 (3.4)
Louisiana 16,655 (4.0) 1028 (2.9) 6518 (3.5) 52,029 (3.7) 25,914 (3.2)
New Jersey 32,691 (7.8) 2533 (7.1) 14,790 (8.0) 11,6078 (8.2) 61,789 (7.6)
Greater Georgia 18,020 (4.3) 1455 (4.1) 7326 (4.0) 61,098 (4.3) 33,288 (4.1)
Marital status (%) <.001
Single (never married) 45,837 (11.0) 14,241 (39.7) 28,521 (15.4) 152,755 (10.8) 86,919 (10.7)
Married 243,841 (58.6) 15,987 (44.5) 111,847 (60.6) 917,527 (64.6) 457,773 (56.2)
Separated 5335 (1.3) 256 (0.7) 2059 (1.1) 13,310 (0.9) 9140 (1.1)
Divorced 28,769 (6.9) 1890 (5.3) 14,371 (7.8) 89,958 (6.3) 73,150 (9.0)
Widowed 72,265 (17.4) 1659 (4.6) 15,267 (8.3) 123,927 (8.7) 152,960 (18.8)
Unmarried or
domestic partner
82 (0.0) 6 (0.0) 42 (0.0) 308 (0.0) 172 (0.0)
Unknown 20,323 (4.9) 1868 (5.2) 12,525 (6.8) 122,553 (8.6) 34,620 (4.2)
Diagnosis year (%) <.001
1973-1980 33,196 (8.0) 3104 (8.6) 20,213 (10.9) 93,134 (6.6) 62,778 (7.7)
1981-1990 57,914 (13.9) 5014 (14.0) 27,208 (14.7) 150,038 (10.6) 106,554 (13.1)
1991-2000 86,342 (20.7) 8589 (23.9) 38,076 (20.6) 344,694 (24.3) 190,433 (23.4)
2001-2010 199,033 (47.8) 16,329 (45.5) 80,587 (43.6) 702,089 (49.4) 377,164 (46.3)
2010-2014 39,967 (9.6) 2871 (8.0) 18,548 (10.0) 130,383 (9.2) 77,805 (9.5)
Vital status (%) <.001
Alive at last contact 186,199 (44.7) 20,948 (58.3) 101,160 (54.8) 779,685 (54.9) 425,184 (52.2)
SM 55,103 (13.2) 2625 (7.3) 30,901 (16.7) 176,096 (12.4) 113,552 (13.9)
ACM 175,150 (42.1) 12,334 (34.3) 52,571 (28.5) 464,557 (32.7) 275,998 (33.9)
Abbreviations: ACM Z all cause mortality; CNS Z central nervous system; IQR Z interquartile ratio; SEERZ Surveillance, Epidemiology, and
End Results; SM Z secondary malignancy.
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SM analysis. This cohort consisted of 35,907 cases of
malignancies in CNS and orbits, 184,632 in head and
neck, 814,734 in thorax, 416,452 in abdomen, and
1,420,338 in pelvis. Excluding patients who were
reported as alive at last contact, ACM is significantly
more likely as an outcome compared with SM,
representing 34%, 28%, 34%, 42%, and 33% of the
cohorts compared with 7%, 17%, 14%, 13%, and 12% for
SM, for CNS and orbits, head and neck, thorax, abdomen,
and pelvis, respectively. The median follow-up is
7.4 years for the entire study cohort and 7.1 and 7.8 years
for male and females, respectively.
Cumulative incidence of SMs
The cumulative incidences of SM for the entire SEER
cohort stratified by RT status is shown in Figure 1 along
with the P value for the distribution of the cumulative
incidence of SM. The plot shows statistically significant
higher SM for the RT cohort compared with the no-RT
cohort (P < .001). The SM rates at 20 years after initial
diagnosis for patients receiving RT versus no RT were
21.4% versus 18.8%. The SM rates at 40 years after initial
diagnosis for patients receiving RT versus no RT were
27.4% versus 24.2%. The relative risk for SM associated
with RT for the overall group was 1.138 and 1.132 at 20
and 40 years, respectively.
Subgroup cumulative incidence of SM by sex
Given that males and females have difference
predilections for malignancies at each anatomic disease
site, we repeated the calculation of cumulative incidence
of SMs for males (N Z 1,477,397) and for females
(N Z 1,394,666) separately, with the cumulative
incidence plots shown in Figure 2. For all primary
malignancies combined, males demonstrated no
difference in SMs between RT and no-RT cohorts
(PZ 1.000), whereas females demonstrated a statistically
significant increase in SMs with RT (P < .001).
Subgroup cumulative incidence of SM by sex and
by anatomic disease sites
The subgroup cumulative incidence plots for SM and
ACM by anatomic disease sites are shown in Figures 3
and 4 for males and females, respectively. For males,
patients who received RT had statistically significant
lower cumulative incidence of SM for CNS and orbits
(P < .001), head and neck (PZ .05), thorax (P < .001),
and abdomen (P < .001) primaries and higher cumulative
incidence of SM for pelvis (P < .001) primaries. For
females, RT resulted in a statistically significant lower
cumulative incidence of SM for CNS and orbits(PZ .003), abdomen (PZ .001), and pelvis (PZ .007)
primaries and a higher cumulative incidence of SM for
head and neck (P < .001) and thorax (P < .001)
primaries. The relative risks for SM associated with RT to
primary malignancies arising from CNS and orbits,
head and neck, thorax, abdomen, and pelvis at 20 years
were 0.704, 1.011, 0.559, 0.646, and 1.106 for men
and 0.792, 1.298, 1.265, 0.780, and 0.988 for
women. For men, the 20-year actuarial rate of SMs
without RT was 0.126 (95% confidence interval [CI],
0.117-0.134), 0.274 (0.269-0.279), 0.220 (0.216-0.224),
0.224 (0.221-0.226), and 0.189 (0.188-0.191) for CNS
and orbits, head and neck, thorax, abdomen, and
pelvis, respectively, and 0.088 (0.081-0.097), 0.276
(0.271-0.282), 0.123 (0.117-0.128), 0.145 (0.132-0.158),
and 0.209 (0.207-0.211) for with RT. For women, the
20-year actuarial rate of SMs without RT was 0.102
(0.094-0.111), 0.169 (0.165-0.173), 0.190 (0.188-0.191),
0.159 (0.157-0.161), and 0.169 (0.167-0.171) for CNS
and orbits, head and neck, thorax, abdomen, and
pelvis and 0.080 (0.072-0.088), 0.218 (0.211-0.225),
0.240 (0.237-0.242), 0.126 (0.111-0.141), and 0.167
(0.164-0.171) with RT.
Subgroup cumulative incidence of SM by age
group
Given that age at diagnosis may affect the incidence of
SM, we repeated the calculation of cumulative incidence
of SM for patients with age 18, 19 to 40, 41 to 60
and 61 years separately, with the cumulative incidence
plots shown in Figure 5. For all primary malignancies
combined, patients whose primary malignancy was
diagnosed at 18 years of age demonstrated a statistically
significant increase in SM with RT (P < .001), and those
whose primary malignancy was diagnosed at 41 to
60 years of age demonstrated a statistically significant
decrease in SM with RT (P < .001).
Discussion
To study SM, a large population size is needed given
the low incidence of SM, as is a careful choice of proper
statistical methodologies. Because SM is such a
rare event, prospective studies are impractical, and
retrospective (single and multiple institutions) studies
often lack the sample size to achieve statistical
significance. Therefore, a large population-based database
such as the SEER database provides the best context to
elucidate the risk of SM.
With respect to statistical methodology, given the
overall low incidence of SM among patients with cancer,
mortality events represent a much more likely outcome
compared with SM and thus compete with SM. Any
disparity in mortality can thus significantly confound the
Figure 1 Cumulative incidence of second malignancies in the entire Surveillance, Epidemiology, and End Results database cohort.
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when studying radiation-induced SM, given that RT has
historically been recommended to patients who are
deemed inoperable secondary to comorbidities, thus
increasing their risk of overall mortality. The most
common statistical methods for SM analysis consist of
standard incidence ratio and Cox proportional hazards
regression. However, neither methods can account for
ACM as a competing risk event for the SM, and as a
result they may inflate the incidence SM with higher
baseline ACM.14 Furthermore, patients with cancer are
likely enriched for behavioral, environmental, and genetic
factors that affect their likelihood of cancer compared
with the noncancer population. In addition, standard
incidence ratio only allows for investigation of specific
type of SM, not the sum of all SMs. This is important
considering that SM development depends both on dose
and anatomy. Therefore, although patients may have
varying risks of different types of SM, the summation of
all SMs may provide a better estimate of the true
incidence of SM from RT.
Thus, there is a clear need for a statistical method that
can counteract the effect of ACM on the estimation of SM
risk. Satagopan et al proposed that in the analysis of SM,
an ACM event precludes the onset of SM and thus should
be treated as a competing risk event instead of a censoredFigure 2 Cumulative incidence of second maevent.29 A competing risk model has previously been
used in a SEER study of SM associated with EBRT for
prostate cancer,14 as well as in patients who received
brachytherapy in a Dutch single-institution series.30
With an overall cohort size of >2.8 million patients,
we have concluded that RT is indeed associated with a
significant relative increase in SM (P < .001) compared
with patients who received no RT, starting after the first
decade after diagnosis and stabilizing after the
second decade, as shown in Figure 1. When the
cumulative incidence of SM in patients who received RT
and those who did not was separately evaluated for males
and females, only females showed a statistically
significant increase in SM with RT (P < .001), as shown
in Figure 2. On further stratification by anatomic disease
sites, males who received RT had a statistically significant
lower cumulative incidence of SM for CNS and orbits,
head and neck, thorax, and abdomen and a higher
cumulative incidence of SM for pelvis. Females who
received RT had a statistically significant lower
cumulative incidence of SM for CNS and orbits,
abdomen, and pelvis and a higher cumulative incidence of
SM for head and neck and thorax. Therefore, the results
of our study, powered by the largest patient population to
date, indicate that the relationship between RT and SM is
highly complex and varies by sexes, age group, andlignancies in males (A) and females (B).
Figure 3 Cumulative incidence of second malignancies by anatomic site of the primary for males.
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disease sites with significant difference in SM between
the RT and no-RT cohorts, the absolute difference
remains low relative to ACM. Given the goal to assess the
occurrence of SM after RT, we did not analyze and
categorize the different types of SM. It is possible that
some are not true SM. The pathogenesis, treatment, and
prognosis of these different SM types should be the
subject of independent evaluations.
The exact mechanism leading to radiation-induced SM
is a topic of active debate. Radiation dose perceived by
normal tissue during RT consists of primary radiation
within each beam path, as well as secondary radiation
outside of the beam path. Part of the secondary radiation
is due to scatter within the patient and collimator, and part
is due to leakage from the treatment machine.31,32 More
importantly, SMs attributed to secondary radiation in
out-of-field organs such as lungs, esophagus, and stomachmay be significantly modified by environmental and
lifestyle factors, and thus they can present with a plethora
of histologies for each anatomic disease site. In addition
to the uncertainties associated with the location and
histology of SM, the relationship between radiation dose
and SM risk is also an area of active research. Throughout
the years, multiple models have been proposed to estimate
SM risk with respect to radiation dose. All models agree
that for relatively low radiation dose exposure up to
several gray, the SM risk increases in a linear relationship
with radiation dose.33 The rationale behind this is that low
dose radiation may be insufficient to achieve cell kill and
thereby allows cells to survive with sublethal damage that
induces malignant transformation. It is important to note
that this linear model is based on the assumption of a
single whole-body exposure, as in the case of atomic
bomb explosion; therefore, some allowances need to be
made for fractionated RT.34 For radiation exposure at
Figure 4 Cumulative incidence of second malignancies by anatomic site of the primary for females.
744 C. Wang et al Advances in Radiation Oncology: OctobereDecember 2019higher dose past the initial 4 Gy, 3 dose-response models
have been proposed. The linear-no-threshold model
continues the earlier linear relationship between SM and
dose,35 the linear-plateau model achieves a plateau at a
higher dose, and the linear exponential model
demonstrates decreased SM at higher dose due to a
presumed increase in cell sterilization. Together, the
uncertainties surrounding the location and histology of
SM, combined with the lack of understanding of its
relationship with radiation dose, make our decision to use
the broadest definition for SM not only justified, but also
necessary to provide the most accurate estimation of its
risk.
To the best of our knowledge, our study is the largest
to look at the issue of SM after RT. This is the first
investigation of RT-induced SM using the SEER database
in its entirety along with a competing risk model capable
of accounting for ACM as a competing risk event for SM.The analysis was carried out according to an all-inclusive
definition of SM that departs from the traditional narrow
definition of in-field SM. This was done to capture all SM
event and thus render the analysis resilient to variations in
individual anatomy and RT dose distribution. Instead, for
part of the analysis, we grouped the primary disease sites
by anatomic groups of RT delivery site. Chemotherapy
use was removed as a major confounding factor for this
analysis, although one could make the argument that
chemotherapy is an intrinsic part of therapy for patients
with cancer and thus its use should be included for the
analysis to reflect reality in these patients. The analysis
including chemotherapy patients will be the subject of a
separate study.
The observation of RT significantly reducing the
cumulative incidence of SM at some anatomic disease
sites is especially interesting. Several theories may
explain this intriguing phenomenon. First, both primary
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radiation to out-of-field organs may end up sterilizing
occult synchronous malignancies and premalignant
tissues. In addition to radiation’s role in direct tumor kill,
there is also evidence to suggest that radiation can induce
strong antitumor immunity via a mechanism called
immunogenic cell death,36e38 which may have a systemic
effect on the patient and reduce the risk of future
malignancies. Finally, patients who did not receive RT
may have eventually developed late metastases or
recurrences that were mistaken for SM.
In terms of limitations, the SEER database only
records treatment received as the first course of treatment;
therefore, we cannot ascertain whether patients who
initially received no RT had later salvage RT for
recurrence. However, this is likely to be uncommon given
the historical low utilization of RT in the salvage setting,
which, when compounded by the already rare nature of
SM, makes it unlikely to significantly confound our
analysis. In addition, underascertainment of the receipt of
RT in the SEER database has been previously
established, which led to the eventual designation of the
RT variable as an experimental variable.39 However, the
underascertainment of the RT variable biases toward
the null hypothesis and in fact makes the statistically
significant findings in this study even more significant. At
the same time, the variation in underascertainment of RTutilization across different anatomic disease sites may
affect the relative risk of SM associated with RT. Our
study also excluded patients who received chemotherapy
as the first course of treatment because chemotherapy can
also induce SM. A study comparing SEER chemotherapy
data with SEER-Medicare data has determined that SEER
chemotherapy data have an overall sensitivity of
approximately 68%, which translates into an overall
positive predictive value of >85%.40 However, it is
unlikely that the underreporting of chemotherapy affects
the cohorts stratified based on RT status differently.
Because our analysis design focuses on anatomic disease
site rather than specific cancer diagnosis, we were not able
to balance clinical covariates such as stage, histology, and
other patient-specific factors that may contribute to
baseline SM rate. Finally, the SEER database does not
record RT dose, fractionation, or the extent of RT field;
therefore, it is impossible to determine the dose
distribution for patients who received RT. This is
somewhat remedied by the fact that we used an
all-inclusive definition of SM, and we relied on the large
population size of the SEER database to average the
variations in RT field and dose. In addition, by relying on
actual retrospective data for our analysis, we have
concluded there is a significantly lower absolute risk for
SM compared with computed risk using equivalent total
mean body dose and the atomic bomb survival data,41
746 C. Wang et al Advances in Radiation Oncology: OctobereDecember 2019which further accentuates the divide between actual and
perceived SM risk associated with RT.
Another factor that may alter SM incidence is RT
technique, which in recent years has focused on
minimizing radiation dose to normal tissues via image
guidance, improved precision in beam delivery, and
particle therapy. The effect of this evolution is both
interesting and pertinent; however, the study of it will
have to wait for additional years in follow-up to ensure
adequate comparison.
Conclusions
Our study shows that RT tends to be associated with a
statistically significant increase in the cumulative
incidence of SM at some anatomic disease sites, although
it can result in statistically significant decrease in the
cumulative incidence of SM at other anatomic disease
sites, with significant variation based on age and sex.
Despite this, the absolute change in SM associated with
RT remains small. In the decision-making process to use
RT as part of the initial treatment regimen, concerns about
SM should be modulated because the pathogenesis is
likely multifactorial and the potential benefits of RT will
remain high relative to its risk for inducing SM.Acknowledgments
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